Kane Biotech Inc (KNE) — Capital Reinvestment Ratio

Latest as of June 2023: 0.15x

Kane Biotech Inc (KNE) has a Capital Reinvestment Ratio of 0.15x as of June 2023, meaning it reinvests 0% of its operating cash flow (CA$382.38K) in capital expenditures (CA$58.65K). Check Kane Biotech Inc tangible book value ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.15x

Capex / Operating Cash Flow

Operating Cash Flow

CA$382.38K

CAD

Capital Expenditures

CA$58.65K

CAD

Data as of

Jun 2023

Most recent filing

Annual Capital Reinvestment Ratio for Kane Biotech Inc (None–None)

Year-by-year Capital Reinvestment Ratio for Kane Biotech Inc from None to None. See Kane Biotech Inc (KNE) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year	Reinvestment Ratio	Operating CF (CAD)	Capital Expenditures	YoY Change

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow